Ibrutinib Deacryloylpiperidine CAS 330786-24-8 Puritas >99.0% (HPLC)
Nomen chemicum | 3-(4-Phenoxyphenyl) -1H-pyrazolo[3,4-d] pyrimidin-4-amine |
Synonyma | Ibrutinib intermeidato N-2;Ibrutinib Deacryloylpiperidine;Ibrutinib immunditia 8;5-(4-Phenoxyphenyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine;IBT4A;Ibrutinib N-Despiperidinyl Impurity |
CAS Number | 330786-24-8 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C17H13N5O |
M. Pondus | 303.32 |
Liquescens punctum | >262℃(dec.) |
Density | 1.380±0.06 g/cm3 |
Periculum Classis | 6.1;Venenum |
Stipare Group | III |
COA & MSDS | Praesto |
Origin | Shanghai, China |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ad Khaki pulveris |
Lepidium sativum | HNMR, LC-MS |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Damnum in Siccatio | <1.00% |
Unius Max.immunditia | <1.00% |
Totalis immunditias | <1.00% |
Metalla gravia (ut Pb) | <20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Ibrutinib (CAS: 936563-96-1) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.


3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS: 330786-24-8) utilis synthetica media in synthesi Ibrutinib (CAS: 936563-96-1 ).Ibrutinib est genus tyrosine kinase bruton (BTK) inhibitoris, adhiberi potest ad curationem lymphocyticam longam leukemia (CLL) et pallium cellae lymphomae (MCL).MCL et CLL ad lymphoma B-celluli Hodgkin non pertinebant, quod difficile est curare et facile recurrere.Commune chemicum immunotherapyrum scopum non habet, saepe occurrit motus 3 vel 4 adversas.Ibrutinib et B lymphocytes oppugnare potuerunt cum BTK, quae ad informationem, differentiationem et transmissionem necessaria sunt, BTK actionem irreversibiliter inhibent, et tumorem cellularum proliferation et efficaciter superstes inhibent.Ibrutinib celeriter post administrationem oralis absorberi potuit, in 1~2h ad maximam unionem sanguinis, motus adversae unius vel duo pertinent, ergo Ibrutinib nova optio curationis CLL et MCL fiet.
-
Ibrutinib Deacryloylpiperidine CAS 330786-24-8.
-
(S) -1-Boc-3-Hydroxypiperidine CAS 143900-44-1 I...
-
4-Phenoxyphenylboronic Acidum CAS 51067-38-0 Ibru...
-
Ibrutinib CAS 936563-96-1 Puritas >99.5% (HPLC) API
-
Ibrutinib Intermedia CAS 330792-70-6 Munditia >...
-
4-Amino-3-Iodo-1H-Pyrazolo[3,4-d]pyrimidine CAS...
-
1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibruti...
-
3-Hydroxypiperidine CAS 6859-99-0 Ibrutinib Int...
-
4-Aminopyrazolo[3,4-d]pyrimidine CAS 2380-63-4 ...
-
4-Phenoxybenzoicum Acidum CAS 2215-77-2 Ibrutinib I...